SSSho Saito

Sho Saito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sho Saito has a total of 284 co-authors. Here are the top co-authors by number of shared publications:

  • Norio Ohmagari

    Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

    16 shared publications
  • Norio Ohmagari

    Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, JPN

    13 shared publications
  • Shinya Tsuzuki

    AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan

    11 shared publications
  • Mari Terada

    Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

    9 shared publications
  • Kayoko Hayakawa

    Disease Control and Prevention Center, National Center for Global Health and Medicine , 1-21-1 Toyama, Shinjuku-ku 162-8655, Tokyo

    7 shared publications
  • Kayoko Hayakawa

    Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security

    7 shared publications

Latest Publications

  • Open Access

    Clinical and genomic features of Chryseobacterium species isolated from clinical cultures

    by Eriko Muramatsu, Masahiro Suzuki, Yukino Inagaki, Tomoki Ayukawa, Jumpei Yamauchi, Ryota Hase, Takehiro Hashimoto, Naoya Itoh, Yasufumi Matsumura, Hideaki Kato, et al.

    Chryseobacterium species are environmental bacteria occasionally implicated in human infections; however, their clinical and genomic features are not fully characterized. This study investigated the clinical, genotypic, and phenotypic characteristics of Chryseobacterium strains collected through the MultiDrug-Resistant Organisms Clinical Research Network, a multicenter prospective study of patients with carbapenem-resistant gram-negative bacilli isolated at tertiary care hospitals in Japan between April 2019 and March 2024. Among 18 patients with Chryseobacterium spp. confirmed by whole-genome sequencing (WGS), 5 had infection, and 13 were colonized. Bacteremia and pneumonia were the common types of infection. The isolates comprised five species, with Chryseobacterium indologenes and Chryseobacterium culicis being the most frequently detected. Compared with WGS, 16S rRNA gene sequencing demonstrated the highest species-level identification accuracy (93.8%), followed by MALDI Biotyper (50.0%), VITEK-MS (31.3%), and VITEK 2 Blue (31.3%). All systems correctly identified C. indologenes , but other species were frequently misidentified or remained unidentified because of limited database coverage. All isolates exhibited broad β-lactam resistance, including resistance to carbapenems, which was associated with species-specific combinations of metallo-β-lactamase and extended-spectrum β-lactamase genes. Minocycline, trimethoprim-sulfamethoxazole, and cefiderocol retained activity across all species. These findings highlight that diverse Chryseobacterium species, including uncommon ones, can be associated with human infections. Incorporating genomic approaches such as WGS or 16S rRNA gene analysis can improve species-level identification, especially for rare or emerging species. IMPORTANCE: Chryseobacterium species are emerging opportunistic pathogens that pose a diagnostic and therapeutic challenge as they are intrinsically resistant to most β-lactams, including carbapenems, and are often misidentified by routine clinical laboratory systems. In this multicenter study, we show that clinical Chryseobacterium isolates represent greater species diversity than is typically recognized, extending beyond Chryseobacterium indologenes to include uncommon species associated with both infection and colonization. Whole-genome sequencing clarified species assignments, revealed species-specific β-lactamase profiles, and highlighted the limitations of commonly used identification platforms, particularly for species absent from commercial databases. Despite broad β-lactam resistance, cefiderocol, minocycline, and trimethoprim-sulfamethoxazole retained in vitro activity across species. These findings emphasize the need for genomic or sequence-based identification to accurately define the clinical spectrum of Chryseobacterium species, guide interpretation of antimicrobial susceptibility, and improve recognition of these organisms as emerging healthcare-associated pathogens.

  • Open Access

    Genomic analysis of intrahospital transmission of carbapenem-resistant Gram-negative bacteria: a multicentre study in Japan

    by Yasufumi Matsumura, Yohei Doi, Kayoko Hayakawa, Takehiro Hashimoto, Yusuke Tsuda, Sho Saito, Masahiro Suzuki, Aki Sakurai, Koh Shinohara, Keiichiro Mori, et al.

    We aimed to identify genomically defined strain transmission events of carbapenem-resistant Gram-negative bacteria (CRGNB) in hospitals, estimate species-specific transmission rates and identify risk factors for transmission. The study included 708 patients from a Japanese prospective multicentre cohort study, the MultiDrug-Resistant organisms clinical research network, from whom at least one CRGNB isolate was collected between 2019 and 2024 (750 isolates in total). Clinical data were retrieved from electronic medical records, and microbiological analyses were performed at a central reference laboratory. Transmission events were determined via whole-genome sequencing data and single-nucleotide polymorphism-based genomic clustering. We identified 37 genomic clusters associated with intrahospital transmission and 1 associated with interhospital transmission. Ninety-four patients (13%) carried at least one isolate involved in intrahospital transmission, and each transmission event involved two to six patients. Patients with Acinetobacter spp. (60% involved in intrahospital transmission), Enterobacter cloacae complex (23%) and Klebsiella oxytoca complex (59%) were significantly associated with intrahospital transmission and were considered high-risk species groups. Patients with Enterobacterales isolates carrying acquired carbapenemase genes had higher intrahospital transmission rates relative to those without (31% vs. 2%). In multivariable analysis, independent risk factors for patients with intrahospital transmission were overlap in ward and time with other CRGNB-positive patients, carriage of high-risk species groups and acquired carbapenemase genes. In this Japanese multicentre cohort, intrahospital transmission of CRGNB was associated with both microbiological characteristics and patient- and healthcare-related factors, underscoring the need for targeted surveillance and infection prevention strategies.

  • Open Access

    Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan

    by Koji Ohyama, Kohei Uemura, Yasufumi Matsumura, Ryota Hase, Hideaki Kato, Takashi Matono, Naoya Itoh, Takehiro Hashimoto, Go Yamamoto, Momoko Mawatari, et al.

    Carbapenem-resistant Enterobacterales (CRE) pose a global threat due to limited treatment options and high mortality. Difficult-to-treat resistance (DTR), defined as non-susceptibility to all conventional β-lactams and fluoroquinolones, has primarily been applied to Pseudomonas aeruginosa . However, its relevance for Enterobacterales remains unclear, particularly in regions with a distinct carbapenemase landscape, such as Japan where IMP-type metallo-β-lactamases predominate. We analyzed the MultiDrug-Resistant organisms clinical research network (MDRnet) cohort, a multicenter prospective study conducted at 13 Japanese hospitals between April 2019 and March 2024. This analysis included patients with clinically indicated cultures yielding CRE. Clinical characteristics and outcomes assessed using the desirability of outcome ranking (DOOR) framework and genomic epidemiology characterized by whole-genome sequencing were compared between DTR and non-DTR groups. Among 196 CRE cases, 64 (32.7%) represented infections, including 12 DTR cases (18.8%). Carbapenemase genes were detected in 34/64 infections (53.1%), with similar prevalence in the DTR and non-DTR groups (50.0% vs 53.8%). bla IMP-1 was the most frequently identified carbapenemase gene ( n = 28). The overall 30-day mortality rate was 21.9%, with 16.7% (95% confidence interval [CI], 2.1%–48.4%) in the DTR group and 23.1% (95% CI, 12.5%–36.8%) in the non-DTR group. DOOR outcomes were similar between groups. Appropriate empiric and definitive therapy was less frequently administered in the DTR group. In this cohort, where IMP-type carbapenemases and non-DTR CRE are prevalent, DTR classification did not appear to correlate with 30-day mortality or DOOR outcomes. These findings underscore the importance of regional molecular epidemiology when interpreting clinical outcomes of CRE infections. IMPORTANCE: Difficult-to-treat resistance (DTR) is increasingly used to assess the clinical impact of antimicrobial resistance, but its significance in carbapenem-resistant Enterobacterales (CRE) may vary across molecular epidemiologic settings. In this prospective multicenter study from Japan, where IMP-type carbapenemases predominated, most CRE infections were classified as non-DTR. Whole-genome sequencing also revealed a distinct local clonal structure. DTR was not associated with 30-day mortality or desirability of outcome ranking despite lower rates of appropriate empiric and definitive therapy. Our study highlights the importance of interpreting DTR in CRE within the context of regional molecular epidemiology and supports the need for continued regional multicenter studies to evaluate its clinical utility.


  • Open Access

    Clinical Performance of the Loop-Mediated Isothermal Amplification Method Compared With Reverse Transcriptase Polymerase Chain Reaction for COVID-19 Diagnosis in Indonesia and the Philippines

    by Ryo Mizushima, Ivet M Suriapranata, Nelson Geraldino, Tri S Kurniasih, Febi Andriani, Ratna S Wijaya, Nata P Lugito, Michele Hernandez-Diwa, Mark A Ang, Gabriel M Ozoa, et al.

    Real-time reverse transcriptase polymerase chain reaction (RT-PCR) is considered the gold standard for the diagnosis of coronavirus disease 2019 (COVID-19); however, this method is expensive, time-consuming, and requires skilled personnel. Therefore, this study aimed to evaluate the clinical performance of loop-mediated isothermal amplification (LAMP), a simpler test method.

  • Open Access

    Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial

    by Toshihiro Kita, Norio Ohmagari, Sho Saito, Hiroshi Mukae, Takahiro Takazono, Taka-Aki Nakada, Tadanaga Shimada, Yuji Hirai, Yuichiro Shindo, Kosaku Komiya, et al.

    Adrenomedullin (AM) is a bioactive peptide that is strongly induced during severe inflammation, including pneumonia and sepsis, and serves as an organ-protective factor. The plasma concentration of AM is markedly increased in the novel coronavirus disease COVID-19 and is closely related to the severity of the disease and prognosis of patients. We performed two investigator-initiated trials to evaluate the efficacy and safety of AM in patients with moderate-to-severe COVID-19. This multicenter, double-blind, placebo-controlled phase-2a trial evaluated COVID-19 patients with severe (n = 33) and moderate (n = 31) pneumonia in Japan. Patients were randomly assigned to receive either 15 ng/kg/min AM or placebo. The primary endpoint was the duration of mechanical ventilation (MV) for severe pneumonia and oxygen support for moderate pneumonia. The main secondary endpoint was clinical status up to 30 days after the intervention. No differences in primary or secondary endpoints were observed between the AM and placebo groups in patients with severe or moderate pneumonia. In the severe pneumonia group, three patients in the placebo group died due to respiratory failure, and one patient in the AM group died due to respiratory failure. The respiratory function test at 30 days in the moderate pneumonia group tended to be better than that in the AM group and approached significance (p = 0.073). Although mild adverse events caused by the vasodilatory effects of AM were noted, the safety of AM for treating pneumonia was confirmed. In these trials, we did not observe a definitive efficacy of AM in moderate to severe pneumonia. Alternative strategies for the treatment of AM in pneumonia require further research.

  • Open Access

    Molecular epidemiology and patient outcome of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research network

    by Sho Saito, Aki Sakurai, Yasufumi Matsumura, Kohei Uemura, Ryota Hase, Hideaki Kato, Naoya Itoh, Takehiro Hashimoto, Takashi Matono, Jiefu Yu, et al.

    Background and objectives: Carbapenem-resistant Gram-negative bacilli (CRGNB), especially Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii, are critical pathogens associated with excess morbidity and mortality. To elucidate their molecular epidemiology and clinical outcomes in Japan, patients with CRGNB were enrolled in the MDR organisms clinical research network (MDRnet) consisting of eight tertiary care facilities. Methods: Between 2019 and 2022, 246 unique patients with carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant P. aeruginosa (CRPA) and carbapenem-resistant A. baumannii (CRAB) isolates were prospectively enrolled. Results: A total of 246 isolates were collected from 246 patients, including 78 (31.7%) CRE, 167 (67.9%) CRPA and 1 (0.4%) CRAB. For CRE, 74.4% of the isolates carried carbapenemase genes with predominance of blaIMP (64.1%). Only 2.4% of CRPA had carbapenemase genes, which was lower than CRE. Among the infected patients, 20.0% and 12.5% died of CRE and CRPA within 30 days, respectively. In patients with CRE, the mortality rate within 30 days for those without carbapenemase-producing Enterobacterales (CPE) was higher compared with those with CPE (22.2% compared with 18.8%). Conclusions: Our study highlights the unique molecular epidemiology and clinical outcomes of CRGNB in Japan.


  • Open Access

    Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals

    by Mari Terada, Sho Saito, Satoshi Kutsuna, Noriko Kinoshita-Iwamoto, Tomiteru Togano, Akira Hangaishi, Katsuyuki Shiratori, Yuki Takamatsu, Kenji Maeda, Yukihito Ishizaka, et al.

    Convalescent plasma therapy, which involves administering plasma from recovered coronavirus disease 2019 (COVID-19) patients to infected individuals, is being explored as a potential treatment for severe cases of COVID-19. This study aims to evaluate the efficacy and safety of convalescent plasma therapy in COVID-19 patients with moderate to severe illness. An open-label, single-arm intervention study was conducted without a control group. Plasma collected from recovered COVID-19 patients was administered to eligible participants. The primary endpoint was the proportion of patients who were placed on artificial ventilation or died within 14 days of transfusion. Secondary endpoints included clinical improvement, viral load measurements, and adverse event monitoring. A total of 59 cases were included in the study. The primary endpoint was evaluated by comparing the rate obtained in the study to an existing rate of 25%. The study also assessed clinical improvement, viral load changes, and safety endpoints through adverse event monitoring. Convalescent plasma therapy shows potential as a treatment option for COVID-19. This study aimed to provide evidence for the efficacy and safety of this therapy and may contribute to its future use in treating severe cases of COVID-19.

  • Open Access

    Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study

    by Rina Yano, Junko Terada-Hirashima, Yukari Uemura, Noriko Tomita, Yosuke Shimizu, Haruka Iwasaki, Nobumasa Okumura, Tetsuya Suzuki, Sho Saito, Mugen Ujiie, et al.

    Background: In May 2022, a case of monkeypox (currently known as “mpox”) with no history of overseas travel was reported in the United Kingdom, followed by reports of infections reported in Europe, the United States, and other countries worldwide. Due to the significant overlap in immune responses among viruses of the genus Orthopoxvirus (including smallpox virus, mpox virus, and vaccinia virus), it is believed that cross-immunity can be achieved by administering the smallpox virus vaccine. In Japan, a smallpox vaccine (LC16m8 strain vaccine) has been approved; however, there was no regulatory approval for the mpox vaccine during the design of this study. Although it is believed that individuals exposed to the mpox virus may receive smallpox vaccination as mpox prophylaxis, the existing evidence is not clear. Objective: The primary objective was to evaluate the efficacy of the LC16m8 strain vaccine, approved for smallpox in Japan, for postexposure prophylaxis against mpox when administered to close contacts of individuals with mpox. The secondary objective was to investigate the safety of the vaccine for postexposure prophylaxis against mpox. Methods: The study aimed to enroll 100 vaccinated participants who had been identified as close contacts of individuals with mpox. Consent was obtained, and the participants are inoculated with the vaccine. Daily recordings of symptoms (body temperature, headache, rash, and side effects) were made until day 21 and then again on day 28. Furthermore, additional evaluations of adverse events were performed by the investigators on days 7, 14, 21, and 28. Considering that the maximum incubation period for mpox is 21 days, the primary end point is the presence or absence of the disease 21 days after close contact. The primary analysis focused on cases within 4 days of intense contact as it has been reported that vaccination within this timeframe can reduce the incidence of the disease. Results: The first trial participant was enrolled on July 28, 2022, and the research period concluded in March 2023. The study results will be published in a peer-reviewed scientific journal. Conclusions: This study allowed us to investigate the efficacy and safety of the LC16m8 strain vaccine in postexposure prophylaxis against mpox. Trial Registration: Japan Registry of Clinical Trials jRCTs031220137; https://jrct.niph.go.jp/en-latest-detail/jRCTs031220137 International Registered Report Identifier (IRRID): DERR1-10.2196/46955


  • Open Access

    Efficacy and Viral Dynamics of Tecovirimat in Patients with MPOX: A Multicenter Open-Label, Double-Arm Trial in Japan

    by Yutaro Akiyama, Shinichiro Morioka, Shinya Tsuzuki, Tomoki Yoshikawa, Masaya Yamato, Hideta Nakamura, Masayuki Shimojima, Mizue Takakusaki, Sho Saito, Kozue Takahashi, et al.

    Introduction: Tecovirimat’s application in treating mpox remains under-researched, leaving gaps in clinical and virological understanding. Methods: The Tecopox study, conducted in Japan, assessed the efficacy and safety of oral tecovirimat therapy in patients with smallpox or mpox. Patients with mpox enrolled between June 28, 2022, and April 30, 2023, were included. We gathered demographic and clinical details along with blood, urine, pharyngeal swab, and skin lesion samples for viral analysis. A multivariable Tobit regression model was employed to identify factors influencing prolonged viral detection. Results: Nineteen patients were allocated to the tecovirimat group. The median age was 38.5 years, and all were male. Ten patients (52.6%) were infected with the human immunodeficiency virus (HIV). Sixteen patients (84.2%) had severe disease. Nine of the 15 patients (60.0%) (four patients withdrew before day 14) had negative PCR results for skin lesion specimens 14 days after inclusion. The mortality rates on days 14 and 30 were 0% and 0%, respectively. No severe adverse events were reported. HIV status and the number of days from symptom onset to tecovirimat administration were associated with lower Ct values ( p = 0.027 and p < 0.001, respectively). The median number of days when PCR testing did not detect the mpox virus in each patient was 19.5 days. Conclusion: The results suggest that early tecovirimat administration might reduce viral shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV appeared to have prolonged viral shedding, increasing the transmission risk compared to those without HIV. Keypoints: The Tecopox study revealed that early tecovirimat administration might reduce viral shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV appeared to have prolonged viral shedding, increasing the transmission risk compared to those without HIV.


  • Open Access

    Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox

    by Tetsuya Suzuki, Sho Saito, Shinya Tsuzuki, Shinobu Ashida, Mizue Takakusaki, Tomoki Yoshikawa, Masayuki Shimojima, Hideki Ebihara, Norio Ohmagari, Shinichiro Morioka

    Introduction: Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022. The effectiveness of tecovirimat has been estimated against smallpox, which belongs to the same Orthopoxvirus genus as monkeypox. Thus, tecovirimat is expected to be effective against monkeypox. This study aims to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox and monkeypox and to prepare a scheme for oral tecovirimat use in Japan. Methods and analysis: This nationwide, multicentre, non-randomised, open-label, double-arm study will involve viral examination of the blood, throat swabs, urine and skin lesions, performed periodically. Participants will freely decide whether to participate in an administered group (supportive treatment plus oral tecovirimat) or a non-administered group (only supportive treatment). Tecovirimat will be administered for 14 days. To ensure that financial problems do not preclude participation in the study, the research fund will cover the cost of tecovirimat and basic hospitalisation fees. The primary endpoint is the percentage of patients with negative PCR results (cycle threshold value ≥40) for skin lesion specimens at 14 days after inclusion in the study. Secondary endpoints include mortality at 14 and 30 days, viral load in each sample, duration of fever and adverse events. The sample size is estimated to be 50 patients with monkeypox or smallpox. Ethics and dissemination: Written informed consent will be obtained from all participants. This study was approved by the Certified Review Board of National Center for Global Health and Medicine and published in the Japan Registry of Clinical Trials. The results of this study will be published in peer-reviewed journals and/or in presentations at academic conferences. Trial registration number: jRCTs031220169.